Overview

A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture

Status:
Withdrawn
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacodynamics, safety, tolerability and pharmacokinetics of indacaterol maleate (QAB149), administered via the EPIC test fixture. The study aims to determine whether the novel device has a similar clinical profile as the established concept 1 device.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals